Tryvio

Tryvio is an oral tablet that lowers blood pressure in adults whose hypertension isn’t managed well despite using multiple medications. It blocks endothelin receptors to relax blood vessels, reducing risks of stroke and heart attack.

Molecule Details :

  • Molecule Name :

    Aprocitentan
  • Innovator :

    IDORSIA PHARMACEUTICALS LTD
  • Approval Date :

    19-Mar-24
  • NCE-1 Date :

    19-Mar-28
  • NCE Date :

    19-Mar-29
  • Dosage Form :

    Tablet
  • Strength :

    12.5mg
  • Therapeutic Category :

    Antihypertensive
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    17
  • 2026 :

    31
  • 2027 :

    49
  • 2028 :

    68
  • 2029 :

    83
  • 2030 :

    86
  • 2031 :

    91
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Choose Spring Bio Solution?

Supported 1000+ Clinical Trials globally

Provides services across regulatory, legal & clinical research

Unmatched intelligence on batches, expiry, spacing, and historical data from innovators

Integrated CRO Services as part of our offerings

Insights on global pricing for smarter clinical trial supply decisions 


Login NCE Grid

Register NCE Grid

Are you sure want to logout from NCE Grid?